Doxil + paclitaxel + cyclophosphamide + bevacizumab

This neoadjuvant combination therapy regimen was developed and evaluated by the University of Alabama at Birmingham for the treatment of locally advanced invasive breast cancer. The regimen consists of the sequential administration of Doxil (liposomal doxorubicin), paclitaxel, and cyclophosphamide, given concurrently with the VEGF inhibitor bevacizumab (Avastin). The primary rationale for this specific combination is the substitution of conventional doxorubicin with its liposomal formulation (Doxil) to potentially reduce the risk of cardiotoxicity, which is a known concern when anthracyclines are combined with bevacizumab. The regimen aims to achieve high rates of pathological complete response (pCR) by utilizing multiple mechanisms of action, including DNA intercalation, microtubule stabilization, DNA alkylation, and inhibition of angiogenesis.

Other names

Sequential Doxil, paclitaxel, and cyclophosphamide with concurrent AvastinDoxil, Paclitaxel, Cyclophosphamide, and Avastin for Locally Advanced Breast Cancer